# Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
Canonical URL: https://biopharmsignal.com/news/APVO/aptevo-and-niowave-launch-strategic-collaboration-for-radiopharmaceutical-therapeutic-development-includes-strategic-equity-investment-by-niowave-at-closing
Ticker: APVO
Company: Aptevo Therapeutics
Source: Aptevo Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://aptevotherapeutics.gcs-web.com
## Summary

50/50 Strategic Collaboration Will Develop Up to Three Radiopharmaceutical Programs Innovation and Investment Continue to Accelerate Across Radiopharmaceutical Oncology SEATTLE, WA AND LANSING, MI / ACCESS Newswire / May 27, 2026 / Aptevo Therapeutics Inc.

## Article Body
50/50 Strategic Collaboration Will Develop Up to Three Radiopharmaceutical Programs Innovation and Investment Continue to Accelerate Across Radiopharmaceutical Oncology SEATTLE, WA AND LANSING, MI / ACCESS Newswire / May 27, 2026 / Aptevo Therapeutics Inc.
## Recent Company News
- 2026-06-30 12:05 EST — [Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors](https://biopharmsignal.com/news/APVO/aptevo-secures-1-5-million-non-dilutive-research-grant-from-the-andy-hill-care-f-0120aa19) — Source: Aptevo Therapeutics
- 2026-06-25 13:46 EST — [Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer](https://biopharmsignal.com/news/APVO/aptevo-therapeutics-appoints-mary-j-janatpour-ph-d-as-senior-vice-president-and-chief-scientific-officer) — Source: Aptevo Therapeutics
- 2026-06-25 13:46 EST — [Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing](https://biopharmsignal.com/news/APVO/aptevo-and-niowave-launch-strategic-collaboration-for-radiopharmaceutical-therapeutic-development-includes-strategic-equity-investment-by-niowave-at-closing) — Source: Aptevo Therapeutics
- 2026-06-25 13:46 EST — [Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection](https://biopharmsignal.com/news/APVO/aptevo-therapeutics-provides-a-1q26-business-update-rainier-on-track-for-2026-completion-and-phase-2-dose-selection) — Source: Aptevo Therapeutics
- 2026-06-25 13:46 EST — [Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update](https://biopharmsignal.com/news/APVO/aptevo-therapeutics-reports-3q25-financial-results-and-provides-a-business-update) — Source: Aptevo Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)